Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 119
Filter
1.
Public Health ; 232: 38-44, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38733959

ABSTRACT

BACKGROUND: While a major goal of community-based participatory research (CBPR) is to improve community health; it is unclear how to measure longstanding success of CBPR. OBJECTIVE: We sought to determine the impact of ongoing CBPR on cardiometabolic health of participating communities, including in people not directly participating in research. METHODS: We used linear mixed-effects modelling with electronic medical records from 2002 to 2012 from the Yukon-Kuskokwim Health Corporation, which provides health care to all Alaska Native people in southwestern Alaska, to compare rates of change in cardiometabolic risk factors between communities that did and did not participate in ongoing CBPR beginning in 2003. RESULTS: We analysed 1,262,035 medical records from 12,402 individuals from 10 study and 38 control communities. Blood pressure declined faster in study than in control communities: systolic blood pressure (0.04 mmHg/year; 95% confidence interval [CI]: 0.01, 0.08); diastolic blood pressure (DBP) (0.07 mmHg/year; 95% CI: 0.04, 0.09). Body mass index increased 0.04 units/year faster in study communities than in control communities (95% CI: 0.03, 0.05). More study visits were associated with faster reduction of DBP and triglyceride levels in study communities. CONCLUSIONS: Ongoing CBPR may improve overall cardiometabolic health in communities, perhaps by increasing engagement in health and advocacy.


Subject(s)
Community-Based Participatory Research , Electronic Health Records , Humans , Male , Female , Middle Aged , Adult , Electronic Health Records/statistics & numerical data , Alaska/epidemiology , Blood Pressure , Cardiometabolic Risk Factors , Alaska Natives/statistics & numerical data , Body Mass Index , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Aged , Young Adult
2.
Int J Immunogenet ; 42(3): 140-6, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25809546

ABSTRACT

Kawasaki disease (KD) is the leading cause of acquired heart disease in children in most developed countries including the United States. The etiology of KD is not known; however, epidemiological and immunological data suggest infectious or immune-related factors in the manifestation of the disease. Further, KD has several hereditary features that strongly suggest a genetic component to disease pathogenesis. Human leucocyte antigen (HLA) loci have also been reported to be associated with KD, but results have been inconsistent, in part, because of small study samples and varying linkage disequilibrium (LD) patterns observed across different ethnic groups. To maximize the informativeness of single nucleotide polymorphism (SNP) genotypes in the major histocompatibility (MHC) region, we imputed classical HLA I (A, B, C) and HLA II (DRB1, DQA1, DQB1) alleles using SNP2HLA method from genotypes of 6700 SNPs within the extended MHC region contained in the ImmunoChip among 112 White patients with KD and their biological parents from North America and tested their association with KD susceptibility using the transmission disequilibrium test. Mendelian consistency in the trios suggested high accuracy and reliability of the imputed alleles (class I = 97.5%, class II = 96.6%). While several SNPs in the MHC region were individually associated with KD susceptibility, we report over-transmission of HLA-C*15 (z = +2.19, P = 0.03) and under-transmission of HLA-B*44 (z = -2.49, P = 0.01) alleles from parents to patients with KD. HLA-B*44 has been associated with KD in other smaller studies, and both HLA-C*15 and HLA-B*44 have biological mechanisms that could potentially be involved in KD pathogenesis. Overall, inferring HLA loci within the same ethnic group, using family-based information is a powerful approach. However, studies with larger sample sizes are warranted to evaluate the correlations of the strength and directions between the SNPs in MHC region and the imputed HLA alleles with KD.


Subject(s)
Genetic Association Studies , Genetic Predisposition to Disease , Histocompatibility Antigens Class II/genetics , Histocompatibility Antigens Class I/genetics , Mucocutaneous Lymph Node Syndrome/genetics , Polymorphism, Single Nucleotide , Alleles , Family , Female , Gene Frequency , Histocompatibility Antigens Class I/immunology , Histocompatibility Antigens Class II/immunology , Humans , Male , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/immunology
4.
Genes Immun ; 15(8): 534-42, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25101798

ABSTRACT

Kawasaki disease (KD) is a diffuse and acute small-vessel vasculitis observed in children, and has genetic and autoimmune components. We genotyped 112 case-parent trios of European decent (confirmed by ancestry informative markers) using the immunoChip array, and performed association analyses with susceptibility to KD and intravenous immunoglobulin (IVIG) non-response. KD susceptibility was assessed using the transmission disequilibrium test, whereas IVIG non-response was evaluated using multivariable logistic regression analysis. We replicated single-nucleotide polymorphisms (SNPs) in three gene regions (FCGR, CD40/CDH22 and HLA-DQB2/HLA-DOB) that have been previously associated with KD and provide support to other findings of several novel SNPs in genes with a potential pathway in KD pathogenesis. SNP rs838143 in the 3'-untranslated region of the FUT1 gene (2.7 × 10(-5)) and rs9847915 in the intergenic region of LOC730109 | BRD7P2 (6.81 × 10(-7)) were the top hits for KD susceptibility in additive and dominant models, respectively. The top hits for IVIG responsiveness were rs1200332 in the intergenic region of BAZ1A | C14orf19 (1.4 × 10(-4)) and rs4889606 in the intron of the STX1B gene (6.95 × 10(-5)) in additive and dominant models, respectively. Our study suggests that genes and biological pathways involved in autoimmune diseases have an important role in the pathogenesis of KD and IVIG response mechanism.


Subject(s)
Genetic Predisposition to Disease/genetics , Immunoglobulins, Intravenous/therapeutic use , Mucocutaneous Lymph Node Syndrome/drug therapy , Mucocutaneous Lymph Node Syndrome/genetics , 3' Untranslated Regions/genetics , Child , Child, Preschool , Female , Fucosyltransferases/genetics , Genetic Predisposition to Disease/ethnology , Genotype , Genotyping Techniques/methods , Humans , Infant , Introns/genetics , Logistic Models , Male , Mucocutaneous Lymph Node Syndrome/ethnology , Multivariate Analysis , Nuclear Family , Polymorphism, Single Nucleotide , Syntaxin 1/genetics , Treatment Outcome , United States , White People/genetics , Galactoside 2-alpha-L-fucosyltransferase
5.
Genes Immun ; 15(6): 424-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25008864

ABSTRACT

The major histocompatibility complex (MHC) region on chromosome 6p21.3 is suspected to host susceptibility loci for HIV-related Kaposi's sarcoma (HIV-KS). A nested case-control study in the Multicenter AIDS Cohort Study was designed to conduct fine genetic association mapping across central MHC. Individuals co-infected with HIV-1 and human herpes virus-8 who later developed KS were defined as cases (n=354) and were matched 1:1 with co-infected KS-free controls. We report data for new independent MHC class II and III susceptibility loci. In particular, class II HLA-DMB emerged as a strong candidate, with the intronic variant rs6902982 A>G associated with a fourfold increase of risk (odds ratio (OR)=4.09; 95% confidence interval (CI)=1.90-8.80; P=0.0003). A striking multiplicative effect on the estimated risk was associated with further carriage of two non-synonymous variants, rs1800453 A>G (Asp697Gly) and rs4148880 A>G (Ile393Val), in the linked TAP1 gene (OR=10.5; 95% CI=2.54-43.6; P=0.0012). The class III susceptibility variant is moderately associated with HIV-KS and lies within a 120-kb-long haplotype (OR=1.52; 95% CI=1.01-2.28; P=0.047) formed by rs7029 A>G (GPANK1 3' untranslated region), rs1065356 G>A (LY6G6C), rs3749953 A>G (MSH5-SAPCD1 read through) and rs707926 G>A (VARS). Our data suggest that antigen processing by MHC class II molecules is a target pathway in the pathogenesis of HIV-KS.


Subject(s)
Genetic Predisposition to Disease/genetics , HLA-D Antigens/genetics , Major Histocompatibility Complex/genetics , Polymorphism, Single Nucleotide , Sarcoma, Kaposi/genetics , Acquired Immunodeficiency Syndrome/complications , Adult , Alleles , Case-Control Studies , Cohort Studies , Gene Frequency , HIV Infections/complications , Haplotypes , Herpesviridae Infections/complications , Homosexuality , Humans , Male , Risk Factors , Sarcoma, Kaposi/etiology
6.
Psychol Med ; 43(5): 1023-31, 2013 May.
Article in English | MEDLINE | ID: mdl-22975221

ABSTRACT

BACKGROUND: Herpes virus infections can cause cognitive impairment during and after acute encephalitis. Although chronic, latent/persistent infection is considered to be relatively benign, some studies have documented cognitive impairment in exposed persons that is untraceable to encephalitis. These studies were conducted among schizophrenia (SZ) patients or older community dwellers, among whom it is difficult to control for the effects of co-morbid illness and medications. To determine whether the associations can be generalized to other groups, we examined a large sample of younger control individuals, SZ patients and their non-psychotic relatives (n=1852). Method Using multivariate models, cognitive performance was evaluated in relation to exposures to herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and cytomegalovirus (CMV), controlling for familial and diagnostic status and sociodemographic variables, including occupation and educational status. Composite cognitive measures were derived from nine cognitive domains using principal components of heritability (PCH). Exposure was indexed by antibodies to viral antigens. RESULTS: PCH1, the most heritable component of cognitive performance, declines with exposure to CMV or HSV-1 regardless of case/relative/control group status (p = 1.09 × 10-5 and 0.01 respectively), with stronger association with exposure to multiple herpes viruses (ß = -0.25, p = 7.28 × 10-10). There were no significant interactions between exposure and group status. CONCLUSIONS: Latent/persistent herpes virus infections can be associated with cognitive impairments regardless of other health status.


Subject(s)
Cognition Disorders/epidemiology , Cytomegalovirus Infections/epidemiology , Herpes Simplex/epidemiology , Models, Statistical , Neuropsychological Tests/statistics & numerical data , Schizophrenia/epidemiology , Adult , Black or African American/genetics , Black or African American/psychology , Antibodies, Viral/blood , Brain/virology , Case-Control Studies , Chronic Disease , Cognition Disorders/genetics , Cognition Disorders/virology , Cytomegalovirus/immunology , Cytomegalovirus Infections/blood , Educational Status , Employment , Female , Genetic Predisposition to Disease , Herpes Simplex/blood , Humans , Male , Multivariate Analysis , Phenotype , Principal Component Analysis , Schizophrenia/genetics , Schizophrenia/virology , Simplexvirus/immunology
7.
Pathologe ; 33(4): 293-300, 2012 Jul.
Article in German | MEDLINE | ID: mdl-22569927

ABSTRACT

The success of cytology in screening programs for cervical cancer is highly dependent on the smear quality. Interdisciplinary projects which evaluate the smear quality and the results of collection devices could be helpful for an improvement and a successful example for quality improvement is presented here. An average of 83% technically adequate and representative smears was documented for 12 million conventional PAP smears; however only an average of 68% technically adequate and representative smears was found for the group of least successful smear takers of all laboratories. This indicates a potential for improvement. Following an interdisciplinary project on smear quality improvement the average rate of representative smears increased from 69 to 83% and in another project this rate remained stable at 86%. Based on 158,411 conventional smears, representative smears were achieved in 92% using Cervex-Brush®, 86% using Szalay Spatula and 82% Cytobrush methods. The combinations of Cytobrush with the Ayre wooden spatula, cotton wool swab or Szalay Spatula achieved 97%, 94% and 92% representative smears, respectively.


Subject(s)
Early Detection of Cancer/standards , Motivation , Papanicolaou Test , Quality Assurance, Health Care/standards , Quality Improvement/standards , Uterine Cervical Dysplasia/pathology , Uterine Cervical Neoplasms/pathology , Vaginal Smears/standards , Austria , Equipment Design , Female , Guideline Adherence , Humans , Predictive Value of Tests , Quality Control , Vaginal Smears/instrumentation
8.
Schizophr Res ; 139(1-3): 105-9, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22627125

ABSTRACT

UNLABELLED: The role of daily functioning is an integral part of the schizophrenia (SZ) phenotype and deficits in this trait appear to be present in both affected persons and some unaffected relatives; hence we have examined its heritability in our cohort of African American schizophrenia families. There is now ample evidence that deficits in cognitive function can impact family members who are not themselves diagnosed with SZ; there is some, but less evidence that role function behaves likewise. We evaluate whether role function tends to "run in families" who were ascertained because they contain an African American proband diagnosed with SZ. METHODS: We analyzed heritability for selected traits related to daily function, employment, living situation, marital status, and Global Assessment Scale (GAS) score; modeling age, gender, along with neurocognition and diagnosis as covariates in a family based African-American sample (N=2488 individuals including 979 probands). RESULTS: Measures of role function were heritable in models including neurocognitive domains and factor analytically derived neurocognitive summary scores and demographics as covariates; the most heritable estimate was obtained from the current GAS scores (h2=0.72). Neurocognition was not a significant contributor to heritability of role function. CONCLUSIONS: Commonly assessed demographic and clinical indicators of functioning are heritable with a global rating of functioning being the most heritable. Measures of neurocognition had little impact on heritability of functioning overall. The family covariance for functioning, reflected in its heritability, supports the concept that interventions at the family level, such as evidenced-based family psychoeducation may be beneficial in schizophrenia.


Subject(s)
Cognition Disorders/etiology , Family Health , Schizophrenia/complications , Schizophrenia/genetics , Schizophrenic Psychology , Activities of Daily Living , Adolescent , Adult , Black or African American , Aged , Aged, 80 and over , Cognition Disorders/genetics , Employment , Factor Analysis, Statistical , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Phenotype , Psychiatric Status Rating Scales , Severity of Illness Index , Young Adult
9.
Cytopathology ; 21(3): 147-56, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20482722

ABSTRACT

This report of the Editorial Advisory Board of Cytopathology gives the results of a survey of medical practitioners in cytopathology, which aimed to find out their views on the current situation in undergraduate and postgraduate training in their institutions and countries. The results show that training in cytopathology and histopathology are largely carried out at postgraduate level and tend to be organized nationally rather than locally. Histopathology was regarded as essential for training in cytopathology by 89.5% of respondents and was mandatory according to 83.1%. Mandatory cytopathology sections of histopathology were reported by 67.3% and specific examinations in cytopathology by 55.4%. The main deficiencies in training were due to its variability; there were insufficient numbers of pathologists interested in cytology and a consequent lack of training to a high level of competence. Pathologists without specific training in cytopathology signed out cytology reports according to 54.7% of responses, more often in centres where training was 3-6 months or less duration. Although 92.2% of respondents thought that specialist cytology should not be reported by pathologists without experience in general cytopathology, that practice was reported by 30.9%, more often in centres with small workloads. The survey report recommends that 6-12 months should be dedicated to cytopathology during histopathology training, with optional additional training for those wanting to carry out independent practice in cytopathology. Formal accreditation should be mandatory for independent practice in cytopathology. When necessary, temporary placements to centres of good practice should be available for trainees intending to practise independently in cytopathology. There should be adequate numbers of pathologists trained in cytopathology to a high level of competence; some of their time could be released by training cytotechnologists and trainee pathologists to prescreen cytology slides and assess adequacy of fine-needle aspiration samples when immediate diagnosis was not required. The survey demonstrated a clear need for European and international guidelines for training in cytopathology.


Subject(s)
Cytodiagnosis , Education, Medical/statistics & numerical data , Health Care Surveys , Pathology/education , Pathology/statistics & numerical data , Periodicals as Topic , Curriculum , Education, Medical, Undergraduate , Educational Measurement , Geography , Surveys and Questionnaires
10.
Ann Oncol ; 21(3): 448-458, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20176693

ABSTRACT

European Guidelines for Quality Assurance in Cervical Cancer Screening have been initiated in the Europe Against Cancer Programme. The first edition established the principles of organised population-based screening and stimulated numerous pilot projects. The second multidisciplinary edition was published in 2008 and comprises approximately 250 pages divided into seven chapters prepared by 48 authors and contributors. Considerable attention has been devoted to organised, population-based programme policies which minimise adverse effects and maximise benefits of screening. It is hoped that this expanded guidelines edition will have a greater impact on countries in which screening programmes are still lacking and in which opportunistic screening has been preferred in the past. Other methodological aspects such as future prospects of human papillomavirus testing and vaccination in cervical cancer control have also been examined in the second edition; recommendations for integration of the latter technologies into European guidelines are currently under development in a related project supported by the European Union Health Programme. An overview of the fundamental points and principles that should support any quality-assured screening programme and key performance indicators are presented here in a summary document of the second guidelines edition in order to make these principles and standards known to a wider scientific community.


Subject(s)
Mass Screening , Quality Assurance, Health Care/standards , Uterine Cervical Dysplasia/diagnosis , Uterine Cervical Neoplasms/diagnosis , Europe , Female , Humans , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Dysplasia/prevention & control
11.
Schizophr Res ; 114(1-3): 50-6, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19643578

ABSTRACT

An increased prevalence of type 2 diabetes (T2D) in schizophrenia (SCZ) patients has been observed. Exposure to antipsychotics (APs) has been shown to induce metabolic dysregulation in some patients but not all treated patients. We hypothesized that important candidate genes for T2D may increase risk for T2D in African-American patients with SCZ or schizoaffective disorder. The PAARTNERS study comprises African-American families with at least one proband with SCZ or schizoaffective disorder. The current study of PAARTNERS SCZ and schizoaffective disorder cases (N=820) examined single nucleotide polymorphisms (SNPs) within select T2D candidate genes including transcription factor 7-like 2 (TCF7L2), calpain 10 (CAPN10), and ectoenzyme nucleotide pyrophosphatase phosphodiesterase 1 (ENNP1) for association with prevalent T2D. We report the association of TCF7L2 (rs7903146) with T2D under both additive and recessive models for the risk allele T. Specifically, the odds ratio (OR) for having T2D was 1.4 (p=0.03) under an additive model and 2.4 (p=0.004) under a recessive model. We also report a marginally significant TCF7L2 by AP treatment interaction that should be investigated in future studies. CAPN10 (rs3792267) was marginally associated with T2D with OR=1.5 (p=0.08) when considering the model GG vs. AG/AA with risk allele G. ENPP1 (rs1044498) was not associated with T2D. We conclude TCF7L2, a risk factor for T2D in the general population, is also a risk factor for T2D in African-American patients with SCZ or schizoaffective disorder. Research is needed to determine if T2D associated polymorphisms are of interest in the pharmacogenetics and future treatment choices of antipsychotics in African-American patients.


Subject(s)
Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Black or African American/genetics , Diabetes Mellitus, Type 2 , Genetic Predisposition to Disease , Psychotic Disorders/drug therapy , Schizophrenia/drug therapy , Adult , Aged , Calpain/genetics , Diabetes Mellitus, Type 2/chemically induced , Diabetes Mellitus, Type 2/genetics , Family Health , Female , Genetics, Population , Genome-Wide Association Study , Humans , Male , Middle Aged , Odds Ratio , Pharmacogenetics , Phosphoric Diester Hydrolases/genetics , Polymorphism, Single Nucleotide/genetics , Psychotic Disorders/genetics , Pyrophosphatases/genetics , Risk Factors , Schizophrenia/genetics , TCF Transcription Factors/genetics , Transcription Factor 7-Like 2 Protein
12.
Schizophr Res ; 109(1-3): 70-9, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19264455

ABSTRACT

While many studies have sought a window into the genetics of schizophrenia, few have focused on African-American families. An exception is the Project among African-Americans to Explore Risks for Schizophrenia (PAARTNERS), which seeks to identify novel and known risk variation for schizophrenia by genetic analyses of African-American families. We report a linkage study of diagnostic status in 217 African-American families using the Illumina Linkage Panel. Due to assumed incomplete and time-dependent penetrance, we performed linkage analysis using two different treatments of diagnosis: (1) treating both affected and unaffected individuals as informative for linkage (using the program SIBPAL) and (2) treating only affected individuals as informative (using the program MERLIN). We also explore three definitions of affected status: narrowly defined schizophrenia; one broadened to include schizoaffective disorder; and another including all diagnoses indicating psychosis. Several regions show a decrease in the evidence for linkage as the definition broadens 8q22.1 (rs911, 99.26 cM; SIBPAL p-value [p] goes from 0.006 to 0.02), 16q24.3 (rs1006547, 130.48 cM; p from 0.00095 to 0.0085), and 20q13.2 (rs1022689, 81.73 cM; p from 0.00015 to 0.032). One region shows a substantial increase in evidence for linkage, 11p15.2 (rs722317, 24.27 cM; p from 0.0022 to 0.0000003); MERLIN results support the significance of the SIBPAL results (p=0.00001). Our linkage results overlap two broad, previously-reported linkage regions: 8p23.3-p12 found in studies sampling largely families of European ancestry; and 11p11.2-q22.3 reported by a study of African-American families. These results should prove quite useful for uncovering loci affecting risk for schizophrenia.


Subject(s)
Black or African American/genetics , Family , Genetic Linkage , Schizophrenia/genetics , Chromosome Mapping , Female , Genetic Predisposition to Disease/genetics , Genotype , Humans , Male , Pedigree , Polymorphism, Single Nucleotide/genetics , Risk Factors
13.
Blood Cells Mol Dis ; 43(1): 119-28, 2009.
Article in English | MEDLINE | ID: mdl-19297219

ABSTRACT

BACKGROUND: Although multiple reports have documented the influence of CYP2C9 and VKORC1 variants on warfarin dose, risk of over-anticoagulation and hemorrhage, their influence on anticoagulation maintenance and individual proportion of time spent in target INR range (PPTR) is limited. Moreover the potential benefit of genotype-guided dosing implemented after initiation of therapy in a racially diverse population has not been explored. Herein we present the influence of CYP2C9 and VKORC1 C1173T on warfarin response during the first 30 days of therapy. METHODS: Warfarin dose was empirically determined in 250 African Americans 271 European Americans. The influence of CYP2C9 and VKORC1 on rate of INR increase, anticoagulation maintenance, risk of over-anticoagulation, and change in dose over 30 days was evaluated after adjustment for socio-demographic, lifestyle and clinical factors. Possession of variant VKORC1 (+/- variant CYP2C9) genotype was associated with a more rapid attainment of target INR and higher frequency of dose adjustments. Patients possessing variant genotypes spent less time in target range. However adjustment for rate of INR increase rendered the association non-significant. European Americans (but not African Americans) possessing variant VKORC1 (+/- variant CYP2C9) genotype had a higher risk of over-anticoagulation. Neither CYP2C9 nor VKORC1 influenced the risk of minor hemorrhage. CYP2C9 and VKORC1 explained 6.3% of the variance in dose change over the first 30 days of therapy demonstrating that the usefulness of genotype-guided dosing may extend beyond first day of therapy. CONCLUSION: The benefit of genotype-based dose prediction may extend beyond first few days of therapy. Whether genotype-guided dosing will decrease the risk of over-anticoagulation, improve anticoagulation control and most importantly improve outcomes for chronic warfarin users remains to be proven.


Subject(s)
Anticoagulants/administration & dosage , Aryl Hydrocarbon Hydroxylases/metabolism , Mixed Function Oxygenases/metabolism , Polymorphism, Genetic , Warfarin/administration & dosage , Black or African American/genetics , Aged , Anticoagulants/therapeutic use , Aryl Hydrocarbon Hydroxylases/genetics , Cohort Studies , Cytochrome P-450 CYP2C9 , Dose-Response Relationship, Drug , Female , Genotype , Hemorrhage/epidemiology , Humans , International Normalized Ratio , Male , Middle Aged , Mixed Function Oxygenases/genetics , Pharmacogenetics , Prospective Studies , Risk Factors , Vitamin K Epoxide Reductases , Warfarin/therapeutic use , White People/genetics
14.
Cytopathology ; 19(5): 271-8, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18821945

ABSTRACT

Most participating countries have now adopted a triple assessment approach, i.e. clinical,imaging and pathology, to breast diagnosis, with FNAC as the first-line pathological investigation in both screening and symptomatic populations, with the exception of microcalcifications. Pathologists specialized in cytopathology are best qualified to collect and interpret FNAC samples, but this is not always possible or practical. Radiologists involved in breast imaging should ensure that they have the necessary skills to carry out FNAC under all forms of image guidance. Best results are achieved by a combination of both techniques, as shown in the image-guided FNAC in the presence of the cytopathologist. The majority of European countries use similar reporting systems for breast FNAC (C1-C5), in keeping with European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis, although some still prefer descriptive reporting only. When triple assessment is concordant, final treatment may proceed on the basis of FNAC, without a tissue biopsy. ER and PR assessment can be done safely on FNAC material. However, not all institutions may have expertise in doing this. HER-2 protein expression on direct cytological preparations is insufficiently reliable for clinical use, although its use for FISH is possible, if expertise is available. The majority of participants practise a degree of one-stop diagnosis with a cytopathologist present in the out-patient clinic. Formal recognition of the importance of the time spent outside the laboratory, both for cytopathologist and cytotechnologist, is necessary in order to ensure appropriate resourcing. The use of core biopsy (CB) has increased, although not always for evidence-based reasons. CB and FNAC are not mutually exclusive. FNAC should be used in diagnosis of benign, symptomatic lesions and CB in microcalcifications, suspicious FNAC findings and malignancies where radiology cannot guarantee stromal invasion.


Subject(s)
Biopsy, Fine-Needle , Breast Diseases , Breast/pathology , Biopsy, Fine-Needle/standards , Biopsy, Fine-Needle/statistics & numerical data , Breast Diseases/diagnosis , Breast Diseases/pathology , Breast Diseases/therapy , Breast Neoplasms/diagnosis , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Female , Humans , Receptor, ErbB-2/metabolism
15.
Cytopathology ; 18(5): 278-82, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17883689

ABSTRACT

The emphasis of the EFCS Congress held in Venice in October 2006 was on the future of Cytopathology in relation to events in Europe. Much of the discussion centred on the role of human papilloma virus testing and its impact on the provision of cervical screening. The following is a transcript of the discussion that took place at the Advisory Board Meeting for the journal Cytopathology, with some additional written comments received prior to the meeting. A brief summary has been provided as a conclusion by Dr A. Herbert.


Subject(s)
Cytological Techniques , Mass Screening/methods , Papillomavirus Infections/diagnosis , Pathology, Clinical/methods , Uterine Cervical Neoplasms/prevention & control , Europe , Female , Humans , Papillomaviridae/isolation & purification , Uterine Cervical Neoplasms/virology
16.
Pathologe ; 28(5): 354-9, 2007 Sep.
Article in German | MEDLINE | ID: mdl-17661043

ABSTRACT

Urinary cytology is used in the detection of nephrologic and uro-oncologic diseases. The advantages and limitations of cytology for the detection and follow-up of bladder cancer have been well known since Papanicolaou. The low sensitivity of urinary cytology, especially in the detection of more frequent urothelial tumors with low malignancy potential, led to the development of a number of new tumor markers. Nevertheless, the ideal tumor marker for bladder cancer has not yet been found. Cystoscopy combined with cytology is still the most widely accepted method for bladder cancer screening. The acceptance of this method can be improved by the use of case-specific preparation methods of a variety of materials. In addition to the follow-up of bladder cancer, urinary cytology is also used in the follow-up of renal transplant patients and therefore remains a worthwhile method leading to clinically relevant diagnoses.


Subject(s)
Kidney Diseases/pathology , Urinary Tract Infections/pathology , Urinary Tract/cytology , Female , Humans , Kidney Neoplasms/pathology , Papanicolaou Test , Urinary Tract/pathology , Urologic Neoplasms/pathology , Urothelium/cytology , Urothelium/pathology , Vaginal Smears
17.
Cytopathology ; 18(4): 213-9, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17635161

ABSTRACT

There are many different systems of cytology classification used in the member states of the European Union (EU) and many different languages. The following short annexe to Chapter 3 of the European Guidelines for Quality Assurance in Cervical Cancer Screening provides a framework that will allow different terminologies and languages to be translated into standard terminology based on the Bethesda system (TBS) for cytology while retaining the cervical intraepithelial neoplasia (CIN) classification for histology. This approach has followed extensive consultation with representatives of many countries and professional groups as well as a discussion forum published in Cytopathology (2005;16:113). This article will describe the reporting of specimen adequacy, which is dealt with in more detail elsewhere in Chapter 3 of the guidelines, the optional general categorization recommended in TBS, the interpretation/cytology result and other comments that may be made on reports such as concurrent human papillomavirus testing and the use of automation review and recommendations for management. The main categories in TBS will be described in the context of CIN, dyskaryosis and dysplasia terminologies so that all may be translated into the same framework. These guidelines should allow European countries to adapt their terminology in such a way as to make their screening programmes comparable with each other as well as with programmes elsewhere in the world.


Subject(s)
Mass Screening/standards , Quality Assurance, Health Care , Uterine Cervical Neoplasms/diagnosis , Cytodiagnosis/standards , Europe , Female , Humans , Terminology as Topic , Uterine Cervical Neoplasms/pathology , Vaginal Smears/standards
18.
Cytopathology ; 18(2): 67-78, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17397490

ABSTRACT

The quality of a cervical cytology laboratory depends on adequate handling and staining of the samples, screening and interpretation of the slides and reporting of the results. These guidelines give an overview of procedures recommended in Europe to manage the balance between best patient care possible, laboratory quality assurance and cost effectiveness and will be published as a chapter 4 in the European Guidelines for Quality Assurance in Cervical Cancer Screening. The laboratory guidelines include protocols for personnel and organisation, material requirements, handling and analysing cervical samples, recording of results, quality management and communication. The section on quality management is comprehensive and includes protocols for all aspects of internal and external quality assurance. The guidelines are extensively referenced and as far as possible the recommendations are evidence-based.


Subject(s)
Laboratories/standards , Mass Screening/standards , Quality Assurance, Health Care , Uterine Cervical Neoplasms/diagnosis , Cytodiagnosis/standards , Europe , Female , Humans
19.
Genes Brain Behav ; 6(8): 770-5, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17376152

ABSTRACT

Genes involved in cellular mechanisms to repair oxidative damage are strong candidates as etiologic factors for Alzheimer's disease (AD). One important enzyme involved in this mechanism is superoxide dismutase 2 (SOD2). The gene for this enzyme lies within a single haplotype block at 6q25.3, a region showing evidence for linkage to AD in a genome scan. We genotyped four single nucleotide polymorphisms (SNPs) in SOD2 in families of the National Institute of Mental Health-AD Genetics Initiative (ADGI): rs2758346 in the 5' untranslated region (UTR), rs4880 in exon 2, rs2855116 in intron 3 and rs5746136 in the 3'UTR. Under a dominant model, family-based association tests showed significant evidence for association of AD with the first three loci in a candidate gene set of families with individuals having age of onset of at least 50 years and two affected and one unaffected sibling, and in a late-onset subset of families (families with all affected individuals having age of onset of at least 65 years) from the full ADGI sample. The alleles transmitted more frequently to cases than expected under the null hypothesis were T, C, G, and G. Global tests of the transmission of haplotypes indicate that the first two loci have the most consistent association with risk of AD. Because of the high linkage disequilibrium in this small (14 kb) gene, and the presence of 100 SNPs in this gene, 26 of which may have functional significance, additional genotyping and sequencing are needed to identify the functionally relevant SNP. We discuss the importance of our findings and the relevance of SOD2 to AD risk.


Subject(s)
Alzheimer Disease/genetics , Genetic Predisposition to Disease , Linkage Disequilibrium/genetics , Superoxide Dismutase/genetics , Age of Onset , Alzheimer Disease/enzymology , Family , Gene Frequency , Genes, Dominant , Genetic Linkage , Haplotypes , Humans , Pedigree , Polymorphism, Single Nucleotide , Superoxide Dismutase/metabolism
20.
J Dent Res ; 84(9): 806-11, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16109988

ABSTRACT

S. mutans plays a key role in dental caries. The extent to which perinatal events influence the acquisition of S. mutans is unclear. We hypothesized that several maternal factors, including the mode of delivery, influence the initial acquisition of S. mutans in infants. A prospective cohort study was conducted in 156 mother-infant pairs. The study found that maternal gestational age (p = 0.04), S. mutans level (p = 0.02), caries score (p = 0.02), sexually transmitted disease (STD) infection experience (p = 0.01), and family income (p = 0.03) had significant effects on the acquisition of S. mutans. Among infants who became infected, those delivered by Caesarean section acquired S. mutans 11.7 mos earlier than did vaginally delivered infants (p = 0.038). C-section infants harbored a single genotype of S. mutans that was identical to that of their mothers (100% fidelity). Analysis of the data demonstrated the possible perinatal influences on infants' acquisition of a member of the cariogenic microbiota, and its potential effect on caries outcome.


Subject(s)
Cesarean Section , Infectious Disease Transmission, Vertical , Mouth/microbiology , Streptococcal Infections/transmission , Streptococcus mutans/isolation & purification , Analysis of Variance , Dental Caries , Female , Genotype , Gestational Age , Humans , Infant , Logistic Models , Male , Maternal Welfare , Pregnancy , Saliva/microbiology , Social Class , Statistics, Nonparametric , Streptococcus mutans/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...